Australasian Gastro-Intestinal Trials Group
Australia and New Zealand's gastrointestinal cancer trials group, running practice-informing trials in gastric, oesophageal, colorectal and pancreatic cancer, including ctDNA-guided adjuvant studies.
Founded in 1991, AGITG (operating publicly as the GI Cancer Institute) designs and runs investigator-initiated trials across Australia, New Zealand and international partners, with the NHMRC Clinical Trials Centre as its coordinating centre. TOPGEAR tested preoperative chemoradiotherapy in gastric cancer, INTEGRATE established regorafenib activity in refractory gastro-oesophageal cancer, and ASCOLT tested aspirin after colorectal cancer surgery. DYNAMIC-III extends the Australian ctDNA-guided adjuvant programme that began with the DYNAMIC study into stage III colon cancer. AGITG also runs hepatocellular, biliary and neuroendocrine tumour trials and partners with TROG and ANZUP.
- TOPGEAR (gastric chemoradiotherapy)
- INTEGRATE (regorafenib)
- DYNAMIC-III (ctDNA-guided adjuvant therapy)
- ASCOLT (aspirin after colorectal surgery)
Pages like this
not linked directly; found by shared links- InstitutionINCLIVA Biomedical Research Institute / Hospital Clínico Universitario de Valencia
Shares Circulating tumour DNA (ctDNA), Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing, Liquid biopsy (ctDNA).
- Key paperDYNAMIC: a blood test safely halved chemotherapy use after surgery for stage II colon cancer
Shares DYNAMIC, Peter MacCallum Cancer Centre, Circulating tumour DNA (ctDNA), Minimal / molecular residual disease (MRD).
- IdeaA national residual-disease weather service: serial blood tests for every curatively treated patient, pooled
Shares DYNAMIC, Circulating tumour DNA (ctDNA), Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing.
- PersonSarah-Jane Dawson
Shares Peter MacCallum Cancer Centre, Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing, Liquid biopsy (ctDNA).
- IdeaUse tumour DNA in blood to decide when to pause treatment in metastatic cancer
Shares DYNAMIC, Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing, Liquid biopsy (ctDNA).
- IdeaBreak the neutrophil DNA nets that catch tumour cells after surgery
Shares Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing, Liquid biopsy (ctDNA), Pancreatic ductal adenocarcinoma.
- PersonAsh A. Alizadeh
Shares Circulating tumour DNA (ctDNA), Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing, Liquid biopsy (ctDNA).
- IdeaFormally qualify tumour-DNA blood tests as a surrogate endpoint for adjuvant trials
Shares DYNAMIC, Circulating tumour DNA (ctDNA), Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing.